iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Indoco Remedies soars after stellar Q4 performance

17 May 2022 , 01:24 PM

EBIDTA improved by 47.5% to Rs 80.5 crore in Q4 FY22 from Rs 54.6 crore in Q4 FY21. EBIDTA margin was 20.1% in the fourth quarter as against 18.5% in the same period last year. Operating profit jumped by 65.1% YoY to Rs 79.1 crore during the quarter. The company recorded 67.2% increase in standalone net profit to Rs 154.5 crore on a 23.4% rise in net revenues to Rs 1,502.7 crore in FY22 over FY21. Aditi Panandikar, managing director, Indoco Remedies, said, ?An excellent sales growth has resulted in an impressive financial performance inspite of various challenges, primarily higher input and freight costs.? Indoco Remedies is a fully integrated, research-oriented pharma company with presence in 55 countries. Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.